InflaRx IFRX 深 滬
等待開盤 07-18 09:30:00 美东时间
0.8679
+0.018
+2.11%
華盛通- 最 高0.87
- 今 開0.85
- 成交量 24.28万股
- 最 低 0.82
- 昨 收 0.85
- 總市值 5879.77万
- 52周最高 2.815
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 0.7113
- 委 比 -39.76%
- 總股本 6774.71万
- 歷史最高 53.10
- 量 比 0.35
- 振 幅 5.88%
- 歷史最低 0.7113
- 每 手 1
- 風險率 0.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V. received a notice from Nasdaq regarding its common shares trading below the $1.00 minimum bid price requirement for 30 consecutive days. The company has 180 days until January 7, 2026, to regain compliance. If unsuccessful, it may transfer its listing to the Nasdaq Capital Market, potentially gaining an additional 180 days to meet the requirement. The notice does not affect current trading, and InflaRx plans to monitor share prices a...
07-11 20:15
Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem
Jasper shares drop after updated BEACON study shows strong results but faces disruption from compromised drug product lot and halted pipeline programs.
07-08 01:25
美股大行评级 | 潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
潜在涨幅746.15%！Intrusion获Ascendiant Capital升目标价至11美元，维持"买入"评级
06-02 13:32
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Oppenheimer Maintains Outperform on InflaRx, Lowers Price Target to $3
Oppenheimer analyst Andreas Argyrides maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 to $3.
05-30 00:35
InflaRx Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-30 00:34
InflaRx Halts Vilobelimab Phase 3 Trial In Pyoderma Gangrenosum After Futility Finding In Interim Analysis
the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility.
05-28 14:36
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
<p>InflaRx N.V. announced the termination of its Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) due to futility, based on an interim analysis of 30 patients. The company will focus on developing INF904, an oral C5aR inhibitor, with data expected this summer. Vilobelimab remains available for COVID-19 under EU and U.S. authorizations.</p>
05-28 05:30
Oppenheimer Initiates Coverage On InflaRx with Outperform Rating, Announces Price Target of $6
Oppenheimer analyst Andreas Argyrides initiates coverage on InflaRx (NASDAQ:IFRX) with a Outperform rating and announces Price Target of $6.
05-08 22:15
InflaRx GAAP EPS of -€0.13
InflaRx press release (NASDAQ:IFRX): Q1 GAAP EPS of -€0.13. As of March 31, 2025, our total funds available amounted to approximately €65.7 million, comprised of €47.3 million of cash and cash equival...
05-07 19:37
